New Standardized Whole Genomes Released to Improve Quality Control
|
By LabMedica International staff writers Posted on 26 Sep 2016 |

Image: A scanning electron micrograph (SEM) shows an oral squamous cancer cell (white) being attacked by two cytotoxic T-cells (red). The tumor-specific T-cells were developed from the patient’s own immune system, a “personalized cancer vaccine” like those that may be developed in the future with the help of NIST’s standardized human genomes as reference materials (Photo courtesy of R.E. Serda / NCI).
Researchers have expanded the set of tools for more accurate next generation sequencing (NGS) analysis of genomes by developing 4 additional reference materials (RMs) to run as controls for assessing performance of the equipment, chemistry, and data analysis being used.
With the addition of genome RMs to a growing collection of “measuring sticks” for DNA sequencing, the National Institute of Standards and Technology (NIST; Gaithersburg, MD, USA) can now provide laboratories with even more capability to map DNA for genetic testing, medical diagnoses, and development of customized drug therapies. The new RMs feature human genomes for 1 Asian and 3 Ashkenazic Jewish individuals, as well as one RM made up of four microbes commonly used in research.
RMs are critical to properly evaluate NGS and genetic testing methods to increase reliability and effectiveness of precision medicine (personalized medicine). The NIST RMs provide well-characterized, whole genome standards that can help a laboratory evaluate how well its DNA sequencing processes are working.
Biases and "blind spots” for certain sequences contribute to uncertainties or errors in the sequence analysis. These biases can lead to hundreds of thousands of disagreements about the same genome. To better understand these biases, laboratories can now compare their results to the information provided by NIST. The RMs have been extensively characterized with multiple techniques, with the results weighted and analyzed to eliminate as much bias and error as possible.
In 2015, the NIST issued the first genome RM (NIST RM 8398) —detailing the genetic makeup for a woman with European ancestry. The 4 new RMs are: NIST RM 8391: male of Eastern European Ashkenazic Jewish ancestry; NIST RM 8392: son (same as NIST RM 8391), father, and mother who are a family of Eastern European Ashkenazic Jewish ancestry; NIST RM 8393: male of East Asian (Chinese) ancestry; and NIST RM 8375: genomes for 4 bacterial species: Salmonella typhimurium LT2, Staphylococcus aureus, Pseudomonas aeruginosa, and Clostridium sporogenes.
The individual human RMs provide a baseline for comparing and contrasting genes from distinctly different lineages, while the trio mother-father-son RM aids analysis of genetic links between family members. The bacterial genomes come from species that challenge the technical performance of sequencing methods and have been determined by the US Food and Drug Administration (FDA) to have significant relevance to the research of public health issues such as food contamination, antibiotic resistance, and hospital-acquired infections.
The RMs can help increase the ability of DNA sequencing laboratories to be more confident in their reporting of true vs. false positives, and true vs. false negatives, and therefore significantly improve genetic tests used for disease risk prediction, diagnosis, and progression tracking. They also can be used with tools developed by the “Global Alliance for Genomics and Health Benchmarking Team” to further raise confidence level.
Similarly, the standardized microbial genomes in NIST RM 8375 can be used to assess performance of high-throughput methods for microbial DNA sequencing.
The RMs were created by NIST and its partners in the Genome in a Bottle consortium, a group that includes members from the federal government, academia, and industry. The consortium is managed by the Joint Initiative for Metrology in Biology (JIMB), a collaboration between NIST and Stanford University. Through its effort to develop, produce, and distribute a suite of genome RMs, the consortium is providing medical and research laboratories with tools to advance clinical applications of whole genome sequencing, and the FDA with better capability to conduct science-based regulatory oversight of the technology.
All five RMs are available for purchase from the NIST Standard Reference Material program. Each RM sample is characterized for homogeneity (to ensure that each vial contains similar DNA) and stability (to ensure comparability to future batches). The original sources for the RMs are from the “Personal Genome Project,” whose cell lines are hosted at the Coriell Institute for Medical Research.
Next additions to the RM collection may include whole genomes from persons with Hispanic, African, and mixed ancestries, as well as a set containing sequenced genes of both malignant tumor and normal cells from the same individual.
Related Links:
National Institute of Standards and Technology
With the addition of genome RMs to a growing collection of “measuring sticks” for DNA sequencing, the National Institute of Standards and Technology (NIST; Gaithersburg, MD, USA) can now provide laboratories with even more capability to map DNA for genetic testing, medical diagnoses, and development of customized drug therapies. The new RMs feature human genomes for 1 Asian and 3 Ashkenazic Jewish individuals, as well as one RM made up of four microbes commonly used in research.
RMs are critical to properly evaluate NGS and genetic testing methods to increase reliability and effectiveness of precision medicine (personalized medicine). The NIST RMs provide well-characterized, whole genome standards that can help a laboratory evaluate how well its DNA sequencing processes are working.
Biases and "blind spots” for certain sequences contribute to uncertainties or errors in the sequence analysis. These biases can lead to hundreds of thousands of disagreements about the same genome. To better understand these biases, laboratories can now compare their results to the information provided by NIST. The RMs have been extensively characterized with multiple techniques, with the results weighted and analyzed to eliminate as much bias and error as possible.
In 2015, the NIST issued the first genome RM (NIST RM 8398) —detailing the genetic makeup for a woman with European ancestry. The 4 new RMs are: NIST RM 8391: male of Eastern European Ashkenazic Jewish ancestry; NIST RM 8392: son (same as NIST RM 8391), father, and mother who are a family of Eastern European Ashkenazic Jewish ancestry; NIST RM 8393: male of East Asian (Chinese) ancestry; and NIST RM 8375: genomes for 4 bacterial species: Salmonella typhimurium LT2, Staphylococcus aureus, Pseudomonas aeruginosa, and Clostridium sporogenes.
The individual human RMs provide a baseline for comparing and contrasting genes from distinctly different lineages, while the trio mother-father-son RM aids analysis of genetic links between family members. The bacterial genomes come from species that challenge the technical performance of sequencing methods and have been determined by the US Food and Drug Administration (FDA) to have significant relevance to the research of public health issues such as food contamination, antibiotic resistance, and hospital-acquired infections.
The RMs can help increase the ability of DNA sequencing laboratories to be more confident in their reporting of true vs. false positives, and true vs. false negatives, and therefore significantly improve genetic tests used for disease risk prediction, diagnosis, and progression tracking. They also can be used with tools developed by the “Global Alliance for Genomics and Health Benchmarking Team” to further raise confidence level.
Similarly, the standardized microbial genomes in NIST RM 8375 can be used to assess performance of high-throughput methods for microbial DNA sequencing.
The RMs were created by NIST and its partners in the Genome in a Bottle consortium, a group that includes members from the federal government, academia, and industry. The consortium is managed by the Joint Initiative for Metrology in Biology (JIMB), a collaboration between NIST and Stanford University. Through its effort to develop, produce, and distribute a suite of genome RMs, the consortium is providing medical and research laboratories with tools to advance clinical applications of whole genome sequencing, and the FDA with better capability to conduct science-based regulatory oversight of the technology.
All five RMs are available for purchase from the NIST Standard Reference Material program. Each RM sample is characterized for homogeneity (to ensure that each vial contains similar DNA) and stability (to ensure comparability to future batches). The original sources for the RMs are from the “Personal Genome Project,” whose cell lines are hosted at the Coriell Institute for Medical Research.
Next additions to the RM collection may include whole genomes from persons with Hispanic, African, and mixed ancestries, as well as a set containing sequenced genes of both malignant tumor and normal cells from the same individual.
Related Links:
National Institute of Standards and Technology
Latest Molecular Diagnostics News
- Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
- Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
- Two-in-One DNA Analysis Improves Diagnostic Accuracy While Saving Time and Costs
- “Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
- New Tool Maps Chromosome Shifts in Cancer Cells to Predict Tumor Evolution
- Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
- Newly-Identified Parkinson’s Biomarkers to Enable Early Diagnosis Via Blood Tests
- New Blood Test Could Detect Pancreatic Cancer at More Treatable Stage
- Liquid Biopsy Could Replace Surgical Biopsy for Diagnosing Primary Central Nervous Lymphoma
- New Tool Reveals Hidden Metabolic Weakness in Blood Cancers
- World's First Blood Test Distinguishes Between Benign and Cancerous Lung Nodules
- Rapid Test Uses Mobile Phone to Identify Severe Imported Malaria Within Minutes
- Gut Microbiome Signatures Predict Long-Term Outcomes in Acute Pancreatitis
- Blood Test Promises Faster Answers for Deadly Fungal Infections
- Blood Test Could Detect Infection Exposure History
- Urine-Based MRD Test Tracks Response to Bladder Cancer Surgery
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







